Actelion, Carlo Gavazzi, Roche, Sonova: Swiss Equity Preview

The following is a list of companies whose shares may have unusual price changes in Zurich. Stock symbols are in parentheses after company names. Share prices are from the last close.

The Swiss Market Index of the biggest and most actively traded companies dropped 0.9 percent to 6,532.64. The broader Swiss Performance Index lost 0.7 percent to 5,824.16.

Actelion Ltd. (ATLN VX): The Swiss drugmaker is not an impressive buyout target, said Derek Taner of Invesco Ltd., a shareholder of Amgen Inc., the company said to be considering a bid for Actelion. The shares fell 1.6 percent to 55.55 Swiss francs.

Basilea Pharmaceutica AG (BSLN SW): The biotechnology company said it has started the first phase study of its innovative sulfactam antibiotic BAL30072. The shares slipped 1.2 percent to 64.30 francs.

Carlo Gavazzi Holding AG (GAV SW): The railway signaling equipment supplier reported net income of 7.5 million francs ($7.58 million) for the six months ending Sept. 30 and said revenue rose 29 percent to 90.8 million francs during the period. The shares shed 0.5 percent to 190 francs.

Nestle SA (NESN VX): The world’s largest food company will add two “major” plants to its Philippines facilities in the next 10 years, Nestle Philippines Chairman John Miller said at an event today. The shares lost 0.2 percent to 55.45 francs.

Roche Holding AG (ROG VX): The world’s biggest maker of cancer medicines made a five-year agreement with Adcock Ingram Holdings Ltd. for the South African company to sell, promote and distribute two “well-established Roche products” in the country. The shares retreated 1.4 percent to 143.40 francs.

Sonova Holding AG (SOON VX): The hearing-aid maker said it’s voluntarily recalling the HiRes 90k cochlear implant after two instances in which the product experienced a “rare malfunction,” the company said in a statement. The shares declined 0.4 percent to 133.70 francs.

To contact the reporter on this story: Giles Broom in Zurich at gbroom@bloomberg.net.

To contact the editor responsible for this story: David Merritt at dmerritt1@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.